Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial.
about
Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccineVaccines for preventing typhoid feverVaccines for preventing typhoid feverRevisiting typhoid fever surveillance in low and middle income countries: lessons from systematic literature review of population-based longitudinal studiesLive attenuated vaccines for invasive Salmonella infectionsVaccines against invasive Salmonella disease: current status and future directionsRethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areasImmunology of Gut Mucosal VaccinesSalmonella typhi Genomics: Envisaging the Future of Typhoid Eradication.Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005.Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.Overview of the impact of Typhoid and Paratyphoid fever. Utility of Ty21a vaccine (Vivotif®)Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.Travel vaccines and elderly persons: review of vaccines available in the United States.Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children.Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trialRoom temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines.A low gastric pH mouse model to evaluate live attenuated bacterial vaccines.Evaluation of vaccines against enteric infections: a clinical and public health research agenda for developing countriesSafety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909.Vaccination Method Affects Immune Response and Bacterial Growth but Not Protection in the Salmonella Typhimurium Animal Model of Typhoid.Typhoid vaccination - UpdateDevelopment of an Acid-Resistant Salmonella Typhi Ty21a Attenuated Vector For Improved Oral Vaccine Delivery.Geographical distribution of typhoid risk factors in low and middle income countriesTyphoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010.Challenges and Opportunities for Typhoid Fever Control: A Call for Coordinated Action.PCR method to identify Salmonella enterica serovars Typhi, Paratyphi A, and Paratyphi B among Salmonella Isolates from the blood of patients with clinical enteric fever.Oral vaccination of weaned rabbits against enteropathogenic Escherichia coli-like E. coli O103 infection: use of heterologous strains harboring lipopolysaccharide or adhesin of pathogenic strainsPopulation impact of Vi capsular polysaccharide vaccine.Advice for families traveling to developing countries with young children.A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions.Vaccines against cholera, typhoid fever and shigellosis for developing countries.Antibodies in action: role of human opsonins in killing Salmonella enterica serovar TyphiConstruction of an attenuated Salmonella enterica serovar Paratyphi A vaccine strain harboring defined mutations in htrA and yncD.Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.Attenuated Bacterial Vaccines
P2860
Q21245322-B9301715-D297-43FF-B2B4-E3E4E63AEDF8Q24201238-2C5563A7-B569-4EEB-AE2F-4B0A4FF68780Q24244406-607834C6-0186-49C5-95C4-86FF7076BDBFQ26773033-2C42307F-6B9E-4DF0-A75B-2462EEB7411DQ27003066-374923AD-0CE3-4365-B329-E6363E32A885Q27007088-D3A99C1C-6ECF-4224-9D58-E2B344181772Q28308143-4F256CB6-BADC-4397-AF13-C0CAABA49A8FQ28972559-D8CD4475-CE2E-41DB-8774-0438040CE7ECQ30234360-23176DF8-9D36-46E9-B55E-D53FE79EE8F0Q31121277-476AC00C-BB04-4C0E-A0D8-CBBE3A2A7717Q33578033-8E7A8AD1-47EB-4F42-BD75-3A58E00EF290Q33690625-FEDA9C71-2093-4EC6-B4CD-B2A0A2C41CF4Q34007802-5A4A6B51-805E-4651-8909-B715E0E5FBB2Q34008449-8E8A70CD-75C4-4723-BA3B-FFA62DCAF71CQ34392982-11170607-7F25-46FE-9D70-69717FD1A9B9Q34528102-4C87EB7C-6243-4EF9-AD73-21A702DD3648Q34673466-DDDF0941-3B64-4618-9484-F7D1E7A9CDAFQ34711665-ADD07AA8-05AF-46D7-B390-99F0E8863B0CQ35086704-31E5901F-AAF5-47F1-B396-97C01F45FE5BQ35137102-3316FEF4-FCDD-47A6-92F2-E1FAE26B38D2Q35399988-006FE56F-2D93-4512-89A2-96B03F7C5854Q35485187-3F627E5B-EB9A-4255-B1F5-10C9CDBA4BA0Q35729793-6F6288A2-6697-404F-B2AB-AD886EF986A6Q35824212-8DF29296-2C96-4A86-835D-E06D7B8285B1Q35892982-655663E2-CB59-4ECC-9AB8-706C7F5ADBFBQ36145803-BF920855-3E98-4029-BD2A-820746849131Q36213624-2134A35B-4830-4C3D-9A36-8FC535EFA423Q36358881-95B15DC8-C79F-4164-AF5B-88015D1BE012Q36635681-EE6659B4-4506-4785-B7B1-78E96E226373Q36672996-1D66DA0E-EF8B-4059-B7C6-6BDAAD602D65Q36947218-4F27BBBF-A381-48EF-A002-0CE9E7675621Q37744982-3DC4890E-3727-4071-829A-14B981011AA7Q38112517-0B2B7EBD-52C5-49F1-B883-57A6A2532156Q38672074-863ACB96-6CA6-4E27-A54C-FE450A59976DQ39217803-446BEEDE-5441-4ADC-8DFB-7983E5F8E113Q39744171-92033262-80DA-4CBD-B41D-6A83B10E1E68Q40151178-E049EB4F-DDC1-4007-B10D-128C65CFE21FQ40271765-E39005A3-2256-42C8-B217-1C995B644948Q40291567-105E31B3-5FE5-4922-9D97-AA087E6722BCQ57915185-0A3C639A-D053-4607-960F-DCD564B41244
P2860
Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Comparison of enteric-coated c ...... omised controlled field trial.
@en
type
label
Comparison of enteric-coated c ...... omised controlled field trial.
@en
prefLabel
Comparison of enteric-coated c ...... omised controlled field trial.
@en
P2093
P1433
P1476
Comparison of enteric-coated c ...... omised controlled field trial.
@en
P2093
P304
P356
10.1016/0140-6736(90)92266-K
P407
P577
1990-10-01T00:00:00Z